Cancer and immunomodulators in inflammatory bowel diseases. - Wikidata - awgldk - TriplyDB

Cancer and immunomodulators in inflammatory bowel diseases.

Cancer and immunomodulators in inflammatory bowel diseases.

http://www.wikidata.org/entity/Q35534959

about

How I treat my inflammatory bowel disease-patients with thiopurines?Better survival of renal cell carcinoma in patients with inflammatory bowel disease Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.Higher Risk for Hematological Malignancies in Inflammatory Bowel Disease: A Nationwide Population-based Study in Taiwan.Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases.Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study.Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.Cancer Risk in Patients with Intestinal Behçet's Disease: A Nationwide Population-Based Study.

P2860

Q28076561-C06E8456-563E-4A7D-9F73-5A8F44CB1F88 Q36546056-C782F7D4-FEE7-477D-9850-497D3670C311 Q38611360-F9EF7D53-293F-428B-B373-5B34AB06A27F Q38853741-CD371021-38DF-45B9-AA4B-3ADBDD9D9391 Q38857511-55D3E1F4-7616-464E-92E6-D9C2AE2EF937 Q39043418-396D18BC-EC7F-4B6A-99F2-D937D274D2BA Q39050073-8E14454D-A492-43B2-A672-C0DC94ECCA3D Q50078662-BE0A1241-A0A1-4DEF-92A0-B58963B10D16

P2860

Cancer and immunomodulators in inflammatory bowel diseases.

http://www.wikidata.org/entity/Q35534959

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Cancer and immunomodulators in inflammatory bowel diseases.

@ast

Cancer and immunomodulators in inflammatory bowel diseases.

@en

type

label

Cancer and immunomodulators in inflammatory bowel diseases.

@ast

Cancer and immunomodulators in inflammatory bowel diseases.

@en

prefLabel

Cancer and immunomodulators in inflammatory bowel diseases.

@ast

Cancer and immunomodulators in inflammatory bowel diseases.

@en

P1433

Q35534959-81BE6B4B-B668-44E9-BF68-C8CC5F243BC5

P1476

Q35534959-A4860D20-9D47-4E22-9296-18B570318598

P2093

Q35534959-15637DF3-B354-4789-931B-BA3739AB2FCC

Q35534959-1C0A784C-A3CF-44F2-B827-0013CDD437F5

Q35534959-21872A16-36CB-434A-848B-D6F26CF08771

Q35534959-BED90036-D1AC-432A-843F-DC595958F6E3

Q35534959-DC16148F-7B8E-40D4-87D9-4985A50C5F16

P2860

Q35534959-086297BF-ADF7-4F44-992C-1836B2E19024

Q35534959-0D24CDEC-EF5E-4C60-8A64-4915D453EE73

Q35534959-100147BC-99E9-41EA-9B24-DECC7E6BC670

Q35534959-120007E3-1D0A-4A39-93E2-65978F7F5855

Q35534959-1268877C-3F85-4AA5-BC4D-8D64773E3CBB

Q35534959-13337CF8-3B88-4582-8974-59127C8BB6DC

Q35534959-181438CB-1A13-4AC4-95F9-3E3452AF68B5

Q35534959-1966B67E-A33B-4D74-896E-55D8CEA40A06

Q35534959-1C080C0A-690E-46D1-84CC-53FF1F1E668C

Q35534959-1DC4BC82-2434-4DD7-97A8-49DB52710F0F

P304

Q35534959-3DC54392-30B9-4670-B5B0-F1C1A8E047F7

P31

Q35534959-81FB1F42-F061-4DE3-A3C2-F592C2DBB265

P356

Q35534959-2B46E544-8629-4532-9A90-92377D31EA2E

P433

Q35534959-E303BA36-D5E5-421E-BA54-286E2ED424E7

P478

Q35534959-5EA8E253-80E0-4964-BF7C-B00D6430C1D3

P577

Q35534959-5350ACEF-9769-41A5-84D2-014277FAEF0E

P698

Q35534959-E0D0679E-1A5A-44FA-96C8-85457E7B94CA

P921

Q35534959-F9EE6BB1-DC43-4439-8550-7124E3E88132

P356

MIB.0000000000000243

P1433

Inflammatory Bowel Diseases

P1476

Cancer and immunomodulators in inflammatory bowel diseases.

@en

P2093

Carmelina Petruzziello

http://www.w3.org/2001/XMLSchema#string

Emma Calabrese

http://www.w3.org/2001/XMLSchema#string

Francesco Pallone

http://www.w3.org/2001/XMLSchema#string

Livia Biancone

http://www.w3.org/2001/XMLSchema#string

Sara Onali

http://www.w3.org/2001/XMLSchema#string

P2860

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

Infliximab maintenance therapy for fistulizing Crohn's disease

Risks and benefits of infliximab for the treatment of Crohn's disease

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease

Abnormalities of uterine cervix in women with inflammatory bowel disease

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

P304

674-698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MIB.0000000000000243

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25545375

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases